FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022732051> ?p ?o ?g. }

• W2022732051 endingPage "994" @default.
• W2022732051 startingPage "977" @default.
• W2022732051 abstract "HepatologyVolume 13, Issue 5 p. 977-994 Special ArticleFree Access Immunology and the liver Marion Peters, Marion Peters Gastroenterology Division, Washington University School of Medicine, St. Louis, Missouri 63110Search for more papers by this authorJohn Vierling, John Vierling Hepatology Division, Cedars-Sinai Medical Center, Los Angeles, California 90048Search for more papers by this authorM. Eric Gershwin, M. Eric Gershwin Division of Rheumatology, Allergy and Clinical Immunology, University of California School of Medicine, Davis, California 95616Search for more papers by this authorDavid Milich, David Milich Department of Molecular Biology, Scripps Clinic and Research Foundation, La Jolla, California 92037Search for more papers by this authorFrancis V. Chisari, Francis V. Chisari General Clinical Research Center, Scripps Clinic and Research Foundation, La Jolla, California 92037Search for more papers by this authorJay H. Hoofnagle M.D., Corresponding Author Jay H. Hoofnagle M.D. Division of Digestive Diseases and Nutrition, National Institutes of Health, Bethesda, Maryland 20892Building 31, Room 9A23, National Institutes of Health, Bethesda, Md 20892===Search for more papers by this author Marion Peters, Marion Peters Gastroenterology Division, Washington University School of Medicine, St. Louis, Missouri 63110Search for more papers by this authorJohn Vierling, John Vierling Hepatology Division, Cedars-Sinai Medical Center, Los Angeles, California 90048Search for more papers by this authorM. Eric Gershwin, M. Eric Gershwin Division of Rheumatology, Allergy and Clinical Immunology, University of California School of Medicine, Davis, California 95616Search for more papers by this authorDavid Milich, David Milich Department of Molecular Biology, Scripps Clinic and Research Foundation, La Jolla, California 92037Search for more papers by this authorFrancis V. Chisari, Francis V. Chisari General Clinical Research Center, Scripps Clinic and Research Foundation, La Jolla, California 92037Search for more papers by this authorJay H. Hoofnagle M.D., Corresponding Author Jay H. Hoofnagle M.D. Division of Digestive Diseases and Nutrition, National Institutes of Health, Bethesda, Maryland 20892Building 31, Room 9A23, National Institutes of Health, Bethesda, Md 20892===Search for more papers by this author First published: May 1991 https://doi.org/10.1002/hep.1840130529Citations: 103AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 1985; 317: 480– 495. 2 Thomas HC, Montano L, Goodall A, de Koning R, Oladapo J, Wiedman KH. Immunological mechanisms in chronic hepatitis B virus infection. HEPATOLOGY 1982; 2(Suppl): 116S– 121S. 3 Oldstone MBA. Viral persistence. Cell 1989; 56: 517– 520. 4 Franco A, Barnaba V, Natali P, Balsano C, Musca A, Balsano F. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes. HEPATOLOGY 1988; 8: 449– 454. 5 Mondelli MG, Mieli-Vergani G, Alberti A, Vergani B, Portmann B, Eddleston AWLF, Williams R. Specificity of the T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol 1982; 129: 2773– 2781. 6 Pontisso P, Poon HC, Tiollais P, Brechot C. Detection of hepatitis B virus DNA in mononuclear blood cells. Br Med J 1984; 288: 1563– 1566. 7 Abb J, Zachoval R, Eisenburg J, Pape GR, Zachoval V, Deinhardt F. Production of interferon alpha and interferon gamma by peripheral blood leukocytes from patients with chronic hepatitis B virus infection. J Med Virol 1985; 16: 171– 176. 8 Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Monias HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588– 590. 9 Brunetto MR, Oliveri F, Rocca G, Criscuolo D, Chiaberge E, Capalbo M, David E, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. HEPATOLOGY 1989; 10: 198– 202. 10 Oldstone MB, Salvato M, Tishon A, Lewicki H. Virus-lymphocyte interactions. III. Biologic parameters of a virus variant that fails to generate CTL and establishes persistent infection in immunocompetent hosts. Virology 1988; 164: 507– 516. 11 Ahmed R, Oldstone MB. Organ specific selection of viral variants during chronic infection. J Exp Med 1988; 167: 1719– 1724. 12 Unanue ER, Cerottini J-C. Antigen presentation. FASEB J 1990; 3: 2496– 2502. 13 Unanue ER, Allen PM. The basis for the immunoregulatory role of macrophages and other accessory cells. Science 1987; 236: 551– 554. 14 Morrison LA, Braciale VL, Braciale TJ. Distinguishable pathways of viral antigen presentation to T lymphocytes. Immunol Res 1986; 3: 294– 304. 15 Milich DR, Thornton GB, Neurath AR, Kent SB, Michel ML, Tiollais P, Chisari FV. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 1985; 288: 1195– 1199. 16 Neurath AR, Kent SBH, Strick N, Parker K. Identification and chemical synthesis of a host cell receptor binding site of hepatitis B virus. Cell 1986; 46: 429– 436. 17 Thung SN, Gerber MA, Kasambalides EJ, Gilja BK, Keh W, Gerlich WH. Demonstration of pre-S polypeptides of hepatitis B virus in infected livers. HEPATOLOGY 1986; 6: 1315– 1318. 18 Stahl S, Mackay P, Magazin M, Bruce SA, Murray K. Hepatitis B virus core antigen: synthesis in Escherichia coli and application in diagnosis. Proc Natl Acad Sci USA 1982; 79: 1606– 1610. 19 Ou JH, Laub O, Rutter WJ. Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen. Proc Natl Acad Sci USA 1986; 83: 1578– 1582. 20 Van den Oord JJ, de Vos R, Desmet VJ. In situ distribution of major histocompatibility complex products and viral antigens in chronic hepatitis B infection: evidence that HBcAg-containing hepatocytes may express HLA DR antigens. HEPATOLOGY 1986; 6: 981– 989. 21 Thomas HC, Brown D, Labrooy J, Epstein O. T-cell subsets in autoimmune and HBV induced chronic liver disease: a review of the abnormalities and effects of treatment. Liver 1982; 2: 266– 269. 22 Pignatelli M, Waters J, Brown D, Lever A, Iwarson S, Schaff Z, Gerety R, et al. MHC class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection. HEPATOLOGY 1986; 6: 349– 353. 23 Onji M, Lever AML, Saito I, Thomas HC. Defective response to interferons in cells transfected with the hepatitis B virus genome. HEPATOLOGY 1989; 9: 92– 96. 24 Twu JS, Lee CH, Lin PM, Schloemer RH. Hepatitis B virus suppresses expression of human beta interferon. Proc Natl Acad Sci USA 1988; 85: 252– 256. 25 Eddleston ALWF, Mondelli M, Mieli-Vergani G, Williams R. Lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection. HEPATOLOGY 1982; 2 (Suppl): 122S– 127S. 26 Milich DR, McLachlan A. The nucleocapsid of hepatitis B virus is both a T cell-independent and T cell-dependent antigen. Science 1988; 234: 1398– 1401. 27 Milich DR, McLachlan A, Moriarty A, Thornton GB. The immune response to the hepatitis B core antigen (HBcAg): localization of T cell recognition sites within HBcAg/HBeAg. J Immunol 1987; 139: 1223– 1232. 28 Milich DR, Jones JE, McLachlan A, Houghten R, Thornton GB, Hughes JL. Distinction between immunogenicity and tolerogenicity among HBcAg T cell determinants: influence of peptide-MHC interaction. J Immunol 1989; 143: 3148– 3156. 29 Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero: a transgenic model. Proc Natl Acad Sci USA 1990; 87: 6599– 6603. 30 Colucci G, Beazer Y, Cautalippi C, Tackney C. Identification of a major hepatitis B core antigen determinant by using synthetic peptides and monoclonal antibodies. J Immunol 1988; 141: 4376– 4380. 31 Ferrari C, Penna A, Giuberti T, Tong MJ, Ribera E, Fiaccodori F, Chisari FV. Intrahepatic, nucleocapsid antigen-specific T cells in chronic active hepatitis B. J Immunol 1987; 139: 2050– 2058. 32 Ferrari C, Chisari FV, Ribera E, Penna A, Mondelli MU. Functional modulation of hepatitis B core antigen-specific T lymphocytes by an autoreactive T cell clone. J Immunol 1988; 141: 1155– 1160. 33 Zhao W, Egan M, Peters M. Regulation of IgM anti-HBc production in acute viral hepatitis B [Abstract]. HEPATOLOGY 1990; 12: 940. 34 Peters M, Walling DM, Kelly K, Davis GL, Waggoner JG, Hoofnagle JH. Immunologic effects of interferon in man: treatment with human recombinant interferon-alpha suppress in vitro immunoglobulin production in patients with chronic type B hepatitis. J Immunol 1986; 137: 3142– 3152. 35 Liang TJ, Blum HE, Wands JR. Characterization and biological properties of a hepatitis B virus isolated from a patient without hepatitis B virus serologic markers. HEPATOLOGY 1990; 12: 204– 212. 36 Neurath AR, Kent SBH, Strick N. Location and chemical synthesis of a pre-S gene coded immunodominant epitope of hepatitis B virus. Science 1984; 224: 392– 395. 37 Neurath AR, Strick N. Peptides from the pre-S1 region of the hepatitis-B virus envelope protein as components of polyvalent hybrid vaccines. In: RA Lerner, H Ginsberg, RM Chanock, F Brown, eds. Vaccines 89: modern approaches to new vaccines including prevention of AIDS. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989: 473– 478. 38 Itoh Y, Takai E, Ohnuma H, Kitajima K, Tsuda F, Machida A, Mishiro S, et al. A synthetic peptide vaccine involving the product of the pre-S(2) region of the hepatitis B virus DNA: protective efficacy in chimpanzees. Proc Natl Acad Sci USA 1984; 83: 9174– 9178. 39 Milich DR, McLachlan A, Moriarty A, Thornton GB. A single pre-S(1) synthetic peptide can prime antibody production to multiple epitopes within the S, pre-S(2) and pre-S(1) regions of HBsAg. J Immunol 1987; 138: 4457– 4465. 40 Milich DR, McLachlan A, Chisari FV, Kent SBH, Thornton GB. Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of the HBsAg. J Immunol 1986; 137: 315– 322. 41 Milich DR, Hughes JL, McLachlan A, Langeley KE, Thornton GB, Jones JE. Importance of subtype in the immune response to the pre-S(2) region of the hepatitis B surface antigen. J Immunol 1990; 144: 3535– 3543. 42 Ferrari C, Penna A, Bertoletti A, Cavalli A, Valli A, Schianchi C, Fiaccadori F. The pre-S1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man. J Clin Invest 1989; 84: 1314– 1319. 43 Hu KQ, Vierling JM, Siddiqui A. Trans-activation of HLA-DR gene by hepatitis B virus x gene product. Proc Natl Acad Sci USA 1990; 87: 7140– 7144. 44 Jin Y, Shih JW-K, Berkower I. Human T cell response to the surface antigen of hepatitis B virus (HBsAg): endosomal and non-endosomal processing pathways are accessible to both endogenous and exogenous antigen. J Exp Med 1988; 168: 293– 306. 45 Budkowska A, Riottot M, Dubreuil P, Lazizi Y, Brechot C, Sobczak E, Petit M, et al. Monoclonal antibody recognizing pre-S(2) epitope of hepatitis B virus: characerization of pre-S(2) epitope and anti-pre-S(2) antibody. J Med Virol 1988; 20: 111– 125. 46 Cupps TR, Hoofnagle JH, Ellis RW, Miller WJ, Gerin JL, Volkman DJ, Haas-Smith SA. In vitro immune responses to hepatitis B surface antigens S and pre-S2 during acute infection by hepatitis B virus in humans. J Infect Dis 1990; 161: 412– 419. 47 Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, Pinkert CA, et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989; 59: 1145– 1156. 48 Moriyama T, Guilhot S, Klopchin K, Moss B, Pinkert CA, Palmiter RD, Brinster RL, et al. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 1990; 248: 361– 364. 49 Sinha AA, Lopez MT, McDevitt HO. Autoimmune diseases: the failure of self tolerance. Science 1990; 248: 1380– 1388. 50 Mackay IR, Gershwin ME. Molecular basis of mitochondrial autoreactivity in primary biliary cirrhosis. Immunol Today 1989; 10: 315– 318. 51 Kaplan M. Primary biliary cirrhosis. N Engl J Med 1987; 316: 512– 528. 52 Tison V, Callea F, Morisi C, Mancini AM, Desmet VJ. Spontaneous “primary biliary cirrhosis” in rabbits. Liver 1982; 2: 152– 161. 53 Krams SM, Surh CD, Coppel RL, Gershwin ME. Immunization of experimental animals with dihydrolipoamide acetyltransferase as a purified recombinant polypeptide generates mitochondrial autoantibodies but not primary biliary cirrhosis. HEPATOLOGY 1989; 9: 411– 416. 54 Saitoh T, Fujiwara M, Nomoto M, Kaminura K, Asakura H. Histologic studies on the hepatic lesions induced by graft-vs-host in MHC class II disparate hosts compared with primary biliary cirrhosis. Am J Pathol 1989; 135: 301– 307. 55 Vierling JM, Ruderman WB, Jaffee BD, Fennell RH, Claman HN. Hepatic lesions in murine chronic graft-versus-host disease to minor histocompatibility antigens: a reproducible model of nonsuppurative destructive cholangitis. Transplantation 1989; 47: 717– 718. 56 Surh CD, Ahmed-Ansari A, Gershwin ME. Comparative epitope mapping of murine monoclonal and human autoantibodies to human PDH-E2, the major mitochondrial autoantigen of primary biliary cirrhosis. J Immunol 1990; 144: 2647– 2652. 57 Howell CD, Yoder T, Claman HN, Vierling JM. Hepatic homing of mononuclear cells isolated during murine chronic graftversus-host disease. J Immunol 1989; 143: 476– 483. 58 Vierling JM, Emmett M, Howell CD, LaRosa FG. Immunogenicity of isolated bile duct epithelial cells (BDC) in mice exhibiting nonsuppurative destructive cholangitis (NSDC) during chronic graft-vs.-host disease (CGVHD) [Abstract]. HEPATOLOGY 1989; 10: 584. 59 Williams FH, Thiele DL. Delineation of the roles of T cytotoxic and T helper cells in the evolution of nonsuppurative cholangitis during murine graft vs. host disease (GVHD) [Abstract]. HEPATOLOGY 1990; 12: 911. 60 Berg PA, Klein R. Heterogeneity of antimitochondrial antibodies. Semin Liver Dis 1989; 9: 103– 116. 61 Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70kD mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987; 138: 3525– 3531. 62 Yeaman SJ, Danner DJ, Mutimer DJ, Fussey SPM, James OFW, Bassendine MF. Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1988; 1: 1067– 1070. 63 Fussey SPM, Guest JR, James OFW, Bassendine MF, Yeaman SJ. Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci USA 1988; 85: 8654– 8658. 64 Fussey SPM, Ali ST, Guest JR, James OFW, Bassendine MF, Yeaman SJ. Reactivity of primary biliary cirrhosis sera with Escherichia coli dihydrolipoamide acetyltransferase (E2p): characterization of the main immunogenic region. Proc Natl Acad Sci USA 1990; 87: 3987– 3991. 65 Van de Water J, Gershwin ME, Leung P, Ansari A, Coppel RL. The autoepitope of the 74 kD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydrolipoamide acetyltransferase. J Exp Med 1988; 167: 1791– 1799. 66 Van de Water J, Gregeau D, Davis P, Ansari A, Danner D, Leung P, Coppel R, et al. Autoantibodies of primary biliary cirrhosis recognize dihydrolipamide acetyltransferase and inhibit enzyme function. J Immunol 1988; 141: 2321– 2324. 67 Surh CD, Coppel R, Gershwin ME. Structural requirement for autoreactivity on humanpyruvate dehydrogenase-E2, the major autoantigen of primary biliary cirrhosis. J Immunol 1990; 144: 3367– 3374. 68 Krams SM, Dorshkind K, Gerhswin ME. Generation of biliary lesions following transfer of human lymphocytes into SCID mice. J Exp Med 1989; 170: 1919– 1930. 69 Courvalin J-C, Lassoued K, Bartnik E, Blobel G, Wozniak R. The 210-kD nuclear envelope polypeptide recognized by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore. J Clin Invest 1990; 86: 279– 285. 70 Lassoued K, Brenard R, Degos F, Courvalin J-C, Andre C, Danon F, Brouet J-C, et al. Antinuclear antibodies directed to a 200 kD polypeptide of the nuclear envelope in primary biliary cirrhosis: a clinical and immunological study of a series of 150 patients with primary biliary cirrhosis. Gastroenterology 1990; 99: 181– 186. 71 Camerini D, James SP, Stamenkovic I, Seed B. Leu-8 TQ1 is the human equivalent of the MEL-14 lymph node homing receptor. Nature 1989; 342: 78– 82. 72 Suou T, Civeira M, Kanof ME, Moreno-Otero R, Jones EA, James S. Defective immunoregulation in primary biliary cirrhosis: CD4+, Leu-8+ T cells have abnormal activation and suppressor function in vitro. HEPATOLOGY 1989; 10: 408– 413. 73 Meyer zum Büschenfelde K-H, Lohse AW, Manns M, Poralla T. Autoimmunity and liver disease. HEPATOLOGY 1990; 12: 354– 363. 74 Poralla T, Manns M, Dienes HP, Dippold W, Hutterroth TH, Meyer am Büschenfelde K-H. Analysis of liver-specific protein LSP using murine monoclonal antibodies. Eur J Clin Invest 1987; 17: 360– 367. 75 Treichel U, Poralla T, Hess G, Manns M, Meyer zum Büschenfelde K-H. Autoantibodies to human asialoglycoprotein receptor (ASGPR) in autoimmune-type chronic hepatitis. HEPATOLOGY 1990; 11: 606– 612. 76 Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Büschenfelde K-H. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987; 1: 292– 294. 77 Volpes R, Van den Oord JJ, Desmet VJ. Immunohistochemical study of adhesion molecules in liver inflammation. HEPATOLOGY 1990; 12: 59– 65. 78 Autschbach F, Meuer SC, Moebius U, Manns M, Hess G, Meyer zum Büschenfelde K-H, Thoenes W, et al. Hepatocellular expression of lymphocyte function-associated antigen 3 (LFA-3) in chronic hepatitis: a possible role for intrahepatic effector/target interactions and alternative lymphocyte activation. HEPATOLOGY 1991; in press. 79 Fukusato T, Gerber MA, Thung SN, Ferrone S, Schaffner F. Expression of HLA class I antigens on hepatocytes in liver disease. Am J Pathol 1986; 123: 264– 270. 80 Krawitt E, Penner E. Antibodies to nuclear lamins in relatives of patients with autoimmune chronic active hepatitis [Abstract]. HEPATOLOGY 1990; 12: 956. 81 McFarlane BM, Sipos J, Gove CD, McFarlane IG, Williams R. Antibodies against the hepatic asialoglycoprotein receptor perfused in situ preferentially attach to periportal liver cells in the rat. HEPATOLOGY 1990; 11: 408– 415. 82 Manns M, Meyer zum Büschenfelde K-H, Hess G. Autoantibodies against LSP in acute and chronic liver diseases: studies on organ-, species- and disease-specificity. Gut 1980; 21: 955– 961. 83 Manns M, Gerken K, Kyriatsoulis A, Staritz M, Meyer zum Büschenfelde K-H. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987; 1: 292– 294. 84 Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, Poupon R, et al. Chronic active hepatitis associated with anti-liver/kidney microsome antibody type 1: a second type of “autoimmune” hepatitis. HEPATOLOGY 1987; 7: 1333– 1339. 85 Zanger UM, Hauri H-P, Loeper J, Homberg J-C, Meyer UA. Antibodies against human cytochronic P-450 dbl in autoimmune hepatitis type II. Proc Natl Acad Sci USA 1988; 27: 8256– 8260. 86 Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. The major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome p450 dbl. J Clin Invest 1989; 83: 1066– 1072. 87 Manns M, Zanger U, Gerken G, Sullivan KF, Meyer zum Büschenfelde K-H, Meyer UA, Eichelbaum M. Patients with type II autoimmune hepatitis express functionally intact cytochrome P-450 dbl that is inhibited by LKM-1 autoantibodies in vitro but not in vivo. HEPATOLOGY 1990; 12: 127– 132. 88 Beaune PH, Dansette PM, Mansuy D, Kiffel L, Finck M, Amar C, Lenoux JP, et al. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA 1987; 84: 551– 555. 89 Manns M. Autoantibodies and antigens in liver diseases: updated. J Hepatol 1989; 9: 272– 280. 90 Goldfeld AE, Maniatis T. Coordinate viral induction of tumor necrosis factor alpha and interferon beta in human B cells and monocytes. Proc Natl Acad Sci USA 1989; 86: 1490– 1494. 91 Reich N, Evans B, Levy D, Fahey D, Knight E, Darnell JE. Interferon induced transcription of a gene encoding a 15 kDa protein depends on an upstream enhancer element. Proc Natl Acad Sci USA 1987; 84: 6394– 6398. 92 Beresini MH, Lempert MJ, Epstein LB. Overlapping polypeptide induction in human fibroblasts in response to treatment with interferon-alpha, interferon-gamma, interleukin 1 alpha, interleukin 1 beta, and tumor necrosis factor. J Immunol 1988; 104: 485– 493. 93 Perlmutter DH. Cytokines and the hepatic acute phase response. In: GM Matuschak, ed. Multiple system organ failure: hepatic regulation of systemic host defense. New York: Marcel Dekker, 1991: in press. 94 Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987; 56: 727– 777. 95 Zoon KC, Arnheiter H. Studies of the interferon receptors. Pharmacol Ther 1984; 24: 259– 278. 96 Hu R, Gau Y, Liu J, Enterline J, Miller D, Hayes M, Bekisz J, et al. Evidence for multiple binding sites for several species of human lymphoblastoid interferon alpha [Abstract]. J Interferon Res 1990; 10 (Suppl): S157. 97 Shirayoshi Y, Burke PA, Appella E, Ozato K. Interferon-induced transcription of a major histocompatibility class I gene accompanies binding of inducible nuclear factors to the interferon consensus sequence. Proc Natl Acad Sci USA 1988; 85: 5884– 5888. 98 Baglioni C. 2′5′-oligo (A) pathway of interferon action. In: S Baron, GJ Stanton, WR Fleischmann, eds. The interferon system: a current review to 1987. Austin, Texas: University of Texas Press, 1987: 365– 371. 99 Ijzermans JN, Marquet RL. Interferon-gamma: a review. Immunobiology 1989; 179: 456– 473. 100 Schreiber RD. Cytokines: structure, function and their role in immune response amplification. In: B Schwartz, ed. Immunology. Kalamazoo, MI: UpJohn Co., 1991: in press. 101 Peters M. Mechanisms of action of interferons. Semin Liver Dis 1990; 9: 235– 239. 102 Feduchi E, Alonso MA, Carrasco L. Human gamma interferon and tumor necrosis factor exert a synergistic blockade on the replication of herpes simplex virus. J Virol 1989; 63: 1354– 1359. 103 Snapper CM, Paul WE. Interferon gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987; 236: 944– 947. 104 Calderon J, Sheehan KCF, Chance C, Thomas ML, Schreiber RD. Purification and characterization of the human interferongamma receptor from placenta. Proc Natl Acad Sci USA 1988; 85: 4837– 4841. 105 Yap WH, Teo TS, Tan YH. An early event in the interferon-induced transmembrane signaling process. Science 1987; 234: 355– 358. 106 Dinarello CA. Biology of interleukin-1. FASEB J 1988; 2: 108– 115. 107 Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1– 10. 108 Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B, Taniguchi T. Cloning and expression of the human interleukin 6 (BSF-2/IFN beta 2) receptor. Science 1988; 241: 825– 828. 109 Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa M, Matsuda T, Hirano T, et al. IL-6 triggers the association of its receptor with a possible signal transducer, gp 130. Cell 1989; 58: 573– 581. 110 Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S, Degudicibus S, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989; 143: 718– 726. 111 Herold KC, Lancki DW, Moldwin RL, Fitch FW. Immunosuppressive effects of cyclosporin A on cloned T cells. J Immunol 1986; 136: 1315– 1321. 112 Latham PS, Pilaro AM, Echeagaray PL, Varesio L. Interferon-γ and IL-2 induced cytotoxicity of rat Kupffer cells toward N1S1 hepatoma which is not mediated by soluble tumor necrosis factor alpha [Abstract]. HEPATOLOGY 1990; 12: 909. 113 Cupps TR, Fauci AS. Corticosteroid mediated immunoregulation in man. Immunol Rev 1982; 65: 133– 155. 114 Peters M. Immunological aspects of antiviral therapy. Springer Semin Immunopathol 1990; 12: 47– 56 Citing Literature Volume13, Issue5May 1991Pages 977-994 ReferencesRelatedInformation" @default.
• W2022732051 created "2016-06-24" @default.
• W2022732051 creator A5004916033 @default.
• W2022732051 creator A5021954687 @default.
• W2022732051 creator A5029678899 @default.
• W2022732051 creator A5031097411 @default.
• W2022732051 creator A5035898518 @default.
• W2022732051 creator A5071197238 @default.
• W2022732051 date "1991-05-01" @default.
• W2022732051 modified "2023-10-11" @default.
• W2022732051 title "Immunology and the liver" @default.
• W2022732051 cites W1514852311 @default.
• W2022732051 cites W1848552725 @default.
• W2022732051 cites W1964193323 @default.
• W2022732051 cites W1966312399 @default.
• W2022732051 cites W1966388921 @default.
• W2022732051 cites W1966653455 @default.
• W2022732051 cites W1966897576 @default.
• W2022732051 cites W1967481287 @default.
• W2022732051 cites W1968913867 @default.
• W2022732051 cites W1979065792 @default.
• W2022732051 cites W1980751318 @default.
• W2022732051 cites W1981111791 @default.
• W2022732051 cites W1983224547 @default.
• W2022732051 cites W1986073312 @default.
• W2022732051 cites W1987154634 @default.
• W2022732051 cites W1989682360 @default.
• W2022732051 cites W1992682059 @default.
• W2022732051 cites W1993260002 @default.
• W2022732051 cites W1994932951 @default.
• W2022732051 cites W1996548067 @default.
• W2022732051 cites W1998135206 @default.
• W2022732051 cites W2001087990 @default.
• W2022732051 cites W2001298499 @default.
• W2022732051 cites W2008944970 @default.
• W2022732051 cites W2011393733 @default.
• W2022732051 cites W2012090583 @default.
• W2022732051 cites W2013054809 @default.
• W2022732051 cites W2014042634 @default.
• W2022732051 cites W2017492932 @default.
• W2022732051 cites W2018479084 @default.
• W2022732051 cites W2020158775 @default.
• W2022732051 cites W2023178963 @default.
• W2022732051 cites W2024180247 @default.
• W2022732051 cites W2024462000 @default.
• W2022732051 cites W2025452570 @default.
• W2022732051 cites W2028511978 @default.
• W2022732051 cites W2029475514 @default.
• W2022732051 cites W2032081772 @default.
• W2022732051 cites W2032649881 @default.
• W2022732051 cites W2041473358 @default.
• W2022732051 cites W2041647537 @default.
• W2022732051 cites W2047928642 @default.
• W2022732051 cites W2048024207 @default.
• W2022732051 cites W2057181442 @default.
• W2022732051 cites W2057210018 @default.
• W2022732051 cites W2063863464 @default.
• W2022732051 cites W2067204022 @default.
• W2022732051 cites W2068902509 @default.
• W2022732051 cites W2068944545 @default.
• W2022732051 cites W2069480630 @default.
• W2022732051 cites W2072350071 @default.
• W2022732051 cites W2073993963 @default.
• W2022732051 cites W2074313357 @default.
• W2022732051 cites W2075816687 @default.
• W2022732051 cites W2076525857 @default.
• W2022732051 cites W2076684492 @default.
• W2022732051 cites W2080938189 @default.
• W2022732051 cites W2084602326 @default.
• W2022732051 cites W2088228879 @default.
• W2022732051 cites W2093107393 @default.
• W2022732051 cites W2096701375 @default.
• W2022732051 cites W2097493752 @default.
• W2022732051 cites W2101868348 @default.
• W2022732051 cites W2105418394 @default.
• W2022732051 cites W2113296405 @default.
• W2022732051 cites W2117970905 @default.
• W2022732051 cites W2119967316 @default.
• W2022732051 cites W2124731827 @default.
• W2022732051 cites W2146576023 @default.
• W2022732051 cites W2155923923 @default.
• W2022732051 cites W2158541247 @default.
• W2022732051 cites W2177943720 @default.
• W2022732051 cites W2188602119 @default.
• W2022732051 cites W2596643750 @default.
• W2022732051 cites W4239056782 @default.
• W2022732051 cites W4245868295 @default.
• W2022732051 cites W4251461256 @default.
• W2022732051 cites W4301946502 @default.
• W2022732051 cites W2058871036 @default.
• W2022732051 doi "https://doi.org/10.1002/hep.1840130529" @default.
• W2022732051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2030002" @default.
• W2022732051 hasPublicationYear "1991" @default.
• W2022732051 type Work @default.
• W2022732051 sameAs 2022732051 @default.
• W2022732051 citedByCount "123" @default.
• W2022732051 countsByYear W20227320512012 @default.
• W2022732051 countsByYear W20227320512014 @default.

• next